Abstract
The existence of long-lasting cellular reservoirs of HIV-1 is one of the major hurdles in developing effective anti-retroviral therapies. These latently infected cells and tissues efficiently evade immune responses and remain dormant until activated, upon which they can generate a productive HIV-1 infection. This classic scenario of viral latency becomes even more difficult to study and model due to the extreme complexity of translating in vivo virus-cell interactions into a controlled in vitro system. The recent developments and constant improvements upon hematopoietic engraftment of human cells and tissues onto recipient immunocompromised murine scaffolds have made it possible to model complex human innate and adaptive immune responses in a small animal model. Specifically, HIV-1 infection has been successfully modeled in these humanized mice to mimic transmission, pathogenesis, host immune responses, and treatment. Here, we review the complexities surrounding modeling HIV-1 latency in vitro and in vivo and highlight the most recent humanized mouse models that support retroviral infection.
Keywords: HIV-1, latency, HAART, humanized mouse model, HIV INFECTIONS, HIV-1 LATENCY, Primary Cells, Transformed cell lines, Small Animal Models, Latent reservoirs
Current HIV Research
Title: Humanized Mouse Models of HIV-1 Latency
Volume: 9 Issue: 8
Author(s): Rachel V. Duyne, Aarthi Narayanan, Kylene K.-Hall, Mohammed Saifuddin, Leonard Shultz and Fatah Kashanchi
Affiliation:
Keywords: HIV-1, latency, HAART, humanized mouse model, HIV INFECTIONS, HIV-1 LATENCY, Primary Cells, Transformed cell lines, Small Animal Models, Latent reservoirs
Abstract: The existence of long-lasting cellular reservoirs of HIV-1 is one of the major hurdles in developing effective anti-retroviral therapies. These latently infected cells and tissues efficiently evade immune responses and remain dormant until activated, upon which they can generate a productive HIV-1 infection. This classic scenario of viral latency becomes even more difficult to study and model due to the extreme complexity of translating in vivo virus-cell interactions into a controlled in vitro system. The recent developments and constant improvements upon hematopoietic engraftment of human cells and tissues onto recipient immunocompromised murine scaffolds have made it possible to model complex human innate and adaptive immune responses in a small animal model. Specifically, HIV-1 infection has been successfully modeled in these humanized mice to mimic transmission, pathogenesis, host immune responses, and treatment. Here, we review the complexities surrounding modeling HIV-1 latency in vitro and in vivo and highlight the most recent humanized mouse models that support retroviral infection.
Export Options
About this article
Cite this article as:
V. Duyne Rachel, Narayanan Aarthi, K.-Hall Kylene, Saifuddin Mohammed, Shultz Leonard and Kashanchi Fatah, Humanized Mouse Models of HIV-1 Latency, Current HIV Research 2011; 9 (8) . https://dx.doi.org/10.2174/157016211798998781
DOI https://dx.doi.org/10.2174/157016211798998781 |
Print ISSN 1570-162X |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4251 |
![](/images/wayfinder.jpg)
- Author Guidelines
- Bentham Author Support Services (BASS)
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Identification of Novel Anti-inflammatory Agents from Ayurvedic Medicine for Prevention of Chronic Diseases: “Reverse Pharmacology” and “Bedside to Bench” Approach
Current Drug Targets Update on ICOS: A Possible Target for Turning-Off Autoimmunity
Recent Patents on Endocrine, Metabolic & Immune Drug Discovery (Discontinued) Biochemistry and Biology of 2'-Fluoro-2'-Deoxythymidine (FT), A Putative Highly Selective Substrate for Thymidine Kinase Type 2 (TK2)
Current Radiopharmaceuticals CCL2-CCR2 Signaling in Disease Pathogenesis
Endocrine, Metabolic & Immune Disorders - Drug Targets Vaccines for Cytomegalovirus
Infectious Disorders - Drug Targets New Perspectives in HCV Therapy: Entry Inhibitors
Recent Patents on Anti-Infective Drug Discovery Drug Design For Flavivirus Proteases: What Are We Missing?
Current Pharmaceutical Design <i>In Silico</i> Approach to Predict the SARS-COV2 Derived Candidate MiRNAs as a Potential Antiviral Therapy
Current Drug Therapy Thinking Outside the Brain: Immunorregulation in Multiple Sclerosis
Current Immunology Reviews (Discontinued) Structure Function Analysis of West Nile Virus RNA Dependent RNA Polymerase: Molecular Model and Implications for Drug Design
Medicinal Chemistry Recent Advances in the Development of Anti-Infective Prophylactic and/or Therapeutic Agents Based on Toll-Like Receptor (TLRs)
Recent Patents on Anti-Infective Drug Discovery Clinical Applications of Intravenous Immunoglobulins in Child Neurology
Current Pharmaceutical Biotechnology An Update of the Review of Neuropsychological Consequences of HIV and Substance Abuse: A Literature Review and Implications for Treatment and Future Research
Current Drug Abuse Reviews Microglial Activation and its Implications in the Brain Diseases
Current Medicinal Chemistry Five Decades of Cuprizone, an Updated Model to Replicate Demyelinating Diseases
Current Neuropharmacology Neuroprotection and Hypothermia in Infants and Children
Current Drug Targets Novel Phospholipase-Resistant Lipid/Peptide Synthetic Lung Surfactants
Mini-Reviews in Medicinal Chemistry HIV-1 Capsid Inhibitors as Antiretroviral Agents
Current HIV Research Morphology of Atherosclerotic Plaque: Its Feature by Imaging Study
Current Pharmaceutical Design Picornavirus IRES: Structure Function Relationship
Current Pharmaceutical Design